<?xml version='1.0' encoding='UTF-8'?><!DOCTYPE collection SYSTEM 'BioC.dtd'>
<collection>
  <source>SourceData</source>
  <date>00000000</date>
  <key>sourcedata.key</key>
  <document>
    <id>5286381 Figure_1-A-B</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 1-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_1-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. Confocal images show Iba1-immunoreactive microglia and macrophages in RPE/choroid whole mount preparations 48 hours after laser coagulation and intravitreal application of low (0.2 &#181;g) and high (3 &#181;g) dose polySia avDP20 or PBS-vehicle. Laser spots of vehicle-injected SIGLEC11 transgenic (tg) and wild type control animals revealed strong accumulation of activated microglia and macrophages, which was effectively decreased in polySia avDP20-injected SIGLEC11 tg animals and to a lower extent in wild type controls. Representative images out of at least three independent experiments are shown. Scale bar: 50&#181;m. B. Quantification of the average pixel intensity of Iba1-positive area in laser spots reflects accumulation of reactive microglia/macrophages on RPE/choroid whole mounts. In comparison to the accumulation of reactive microglia/macrophages in control animals, there is a reduced pixel intensity found in polySia avDP20-treated SIGLEC11 tg animals. Notably, treatment with a high polySia avDP20 dose (3 &#181;g) also reduced accumulation of microglia/macrophages in laser spots of wild type animals. Data show mean +/- SD. * p&lt; 0.05, ** p&lt; 0.01, *** p&lt; 0.001, One-way ANOVA followed by Fisher's LSD. WT PBS (n = 24 spots), WT 0.2 &#181;g Sia (n = 37 spots), WT 3 &#181;g Sia (n = 20 spots), SIGLEC11 tg PBS (n = 25 spots), SIGLEC11 tg 0.2 &#181;g Sia (n = 35 spots), SIGLEC11 tg 3 &#181;g Sia (n = 31 spots), WT PBS vs WT 3 &#181;g Sia p = 0.0147, WT 0.2 &#181;g Sia vs SIGLEC11 tg 0.2 &#181;g Sia p = 0.0046, SIGLEC11 tg PBS vs SIGLEC11 tg 0.2 &#181;g Sia p = 0.0071, SIGLEC11 tg PBS vs SIGLEC11 tg 3 &#181;g Sia p &lt; 0.0001.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_1-C</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 1-C</infon>
    <infon key="sourcedata_figure_dir">Figure_1-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Confocal images of retinal whole mounts show Iba1-immunoreactive microglial cells. Retinal microglia of polySia avDP20-treated SIGLEC11 tg mice had a more ramified microglial morphology in the laser spot compared to PBS-vehicle treated mice. Interestingly, high polySia avDP20 dose (3 &#181;g) also exerted a weak therapeutic effect in wild type animals. Representative images out of at least three independent experiments are shown. Scale bar: 20 &#181;m. D. Percentage of retina showing activated microglial cells within the laser spots was quantified. PolySia avDP20 reduced the percentage of laser spots with activated microglia in SIGLEC11 tg animals and at high dose (3 &#181;g) also in wild type controls. Data show mean +/- SEM. * p&lt; 0.05, ** p&lt; 0.01, ***p&lt;0.001, One-way ANOVA followed by Fisher's LSD. WT PBS (n = 6 retinas), WT 0.2 &#181;g Sia (n = 8 retinas), WT 3 &#181;g Sia (n = 6 retinas), SIGLEC11 tg PBS (n = 8 retinas), SIGLEC11 tg 0.2 &#181;g Sia (n = 7 retinas), SIGLEC11 tg 3 &#181;g Sia (n = 6 retinas),WT PBS vs WT 3 &#181;g Sia p = 0.0052, WT 0.2 &#181;g Sia vs SIGLEC11 tg 0.2 &#181;g Sia p = 0.0005, SIGLEC11 tg PBS vs SIGLEC11 tg 0.2 &#181;g Sia p = 0.0159, SIGLEC11 tg PBS vs SIGLEC11 tg 3 &#181;g Sia p = 0.001.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_2-A-B</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 2-A-B</infon>
    <infon key="sourcedata_figure_dir">Figure_2-A-B</infon>
    <passage>
      <offset>0</offset>
      <text>A. Fundus fluorescein angiography was performed 48 hours after laser coagulation and intravitreal application of low (0.2 &#181;g) and high (3 &#181;g) dose polySia avDP20 or PBS-vehicle. Late stage (10-11 minutes after fluorescein injection) fundus fluorescein angiography revealed that PBS-treated wild type controls and humanized SIGLEC11 mice showed normal levels of vessel leakage whereas polySia avDP20-treated SIGLEC11 transgenic (tg) mice had lower levels of vessel leakage compared to PBS-injected wild type or SIGLEC11 tg mice. High polySia avDP20 dose reduced vascular leakage also in wild type animals. Representative images out of at least eight independent experiments are shown. B. Fundus fluorescein angiography pictures were exported from Heidelberg Eye Explorer Software and fluorescein leakage was quantified with ImageJ software (NIH). Pixel intensities of 6 regions of interest per picture were quantified and background fluorescence was subtracted. PolySia avDP20-treated SIGLEC11 tg animals showed reduced vascular leakage compared to PBS-injected wild type control and SIGLEC11 tg mice. A reduction in vascular leakage was also observed in high dose polySia avDP20-injected wild type control mice. Data show mean +/- SD. * p&lt; 0.05, *** p&lt; 0.001, One-way ANOVA followed by Fisher's LSD. WT PBS (n = 20 eyes), WT 0.2 &#181;g Sia (n = 17 eyes), WT 3 &#181;g Sia (n = 9 eyes), SIGLEC11 tg PBS (n = 16 eyes), SIGLEC11 tg 0.2 &#181;g Sia (n = 20 eyes), SIGLEC11 tg 3 &#181;g Sia (n = 15 eyes), WT PBS vs WT 3 &#181;g Sia p = 0.0193, WT 0.2 &#181;g Sia vs SIGLEC11 tg 0.2 &#181;g Sia p &lt; 0.0001, SIGLEC11 tg PBS vs SIGLEC11 tg 0.2 &#181;g Sia p &lt; 0.0001, SIGLEC11 tg PBS vs SIGLEC11 tg 3 &#181;g Sia p = 0.0002.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_2-C-D</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 2-C-D</infon>
    <infon key="sourcedata_figure_dir">Figure_2-C-D</infon>
    <passage>
      <offset>0</offset>
      <text>C. Anti-C5b-9 immunostaining of RPE/choroid whole mount preparations 48 hours after laser damage showed strong MAC deposition in the laser lesions of vehicle-injected controls. PolySia avDP20 treatment reduced MAC formation in a dose-dependent fashion independent of SIGLEC11 presence. Scale bar: 100 &#181;m. D. Quantification of C5b-9 fluorescence signal intensity in the laser lesions. In comparison to the high amount of MAC deposition in vehicle-injected controls, the pixel intensity is reduced in polySia avDP20-treated eyes in a dose-dependent fashion and regardless of SIGLEC11 presence. Data show mean +/- SD. *** p&lt; 0.001, One-way ANOVA followed by Fisher's LSD. WT PBS (n = 12 laser spots), WT 0.2 &#181;g Sia (n = 12 laser spots), WT 3 &#181;g Sia (n = 7 laser spots), SIGLEC11 tg PBS (n = 6 laser spots), SIGLEC11 tg 0.2 &#181;g Sia (n = 10 laser spots), SIGLEC11 tg 3 &#181;g Sia (n = 12 laser spots); all statistical comparisons p &lt; 0.0001 except SIGLEC11 tg PBS versus SIGLEC11 tg 0.2 &#181;g Sia p = 0.0004.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-A</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-A</infon>
    <infon key="sourcedata_figure_dir">Figure_3-A</infon>
    <passage>
      <offset>0</offset>
      <text>A. Analysis of relative TNFSF2 gene transcription in human control and SIGLEC11/16 knockout THP1-macrophages. The levels of gene transcripts were reduced after 24 hours of co-treatment with LPS (1 &#181;g/ml) and concentrations of 0.15 &#181;M and 1.5 &#181;M of polySia avDP20 in the human wild type macrophages. No response to polySia avDP20 was detectable in the knockout line. Data show mean +/- SEM. ** p &lt; 0.01, ANOVA followed by Bonferroni. Statistical analysis was done in relation to the LPS control. WT: no treatment n=7 and p&lt; 0.0001, PolySia avDP20 1.5 &#181;M n=4 and p=0.0002, LPS n=7, LPS/PolySia avDP20 0.15&#181;M n=3 and p=0.009, LPS/PolySia avDP20 1.5&#181;M n=5 and p=0.002. Siglec11/16 KO: no treatment n=5 and p=0.01, PolySia avDP20 n=4 and p=0.122, LPS n=7, LPS/PolySia avDP20 0.15&#181;M n=3 and p=1.0, LPS/PolySia avDP20 1.5&#181;M n=4 and p=1.0.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-B</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-B</infon>
    <infon key="sourcedata_figure_dir">Figure_3-B</infon>
    <passage>
      <offset>0</offset>
      <text>B. Analysis of relative TNFSF2 protein release in human control and SIGLEC11/16 knockout THP1-macrophages. The released protein levels were reduced after 24 hours of co-treatment with LPS (1 &#181;g/ml) and concentrations of 0.15 &#181;M and 1.5 &#181;M of polySia avDP20 in the human wild type macrophages. No response to polySia avDP20 was detectable in the knockout line. Data show mean +/- SEM. ** p &lt; 0.01, *** p &lt; 0.001, ANOVA followed by Bonferroni. Statistical analysis was done in relation to the LPS control. WT: no treatment n=8 and p&lt;0.0001, PolySia avDP20 1.5 &#181;M n=5 and p&lt;0.001, LPS n=7, LPS/PolySia avDP20 0.15&#181;M n=5 and p=0.002, LPS/PolySia avDP20 1.5&#181;M n=4 and p=0.0003. Siglec11/16 KO: no treatment n=6 and p&lt;0.001, PolySia avDP20 1.5 &#181;M n=5 and p&lt;0.001, LPS n=7, LPS/PolySia avDP20 0.15&#181;M n=5 and p=1.0, LPS/PolySia avDP20 1.5&#181;M n=5 and p=1.0.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-C</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-C</infon>
    <infon key="sourcedata_figure_dir">Figure_3-C</infon>
    <passage>
      <offset>0</offset>
      <text>C. Analysis of relative VEGFA gene transcription in human control and SIGLEC11/16 knockout THP1-macrophages. Gene transcripts were reduced after 24 hours of co-treatment with LPS (1 &#181;g/ml) and polySia avDP20 (0.15 &#181;M and 1.5 &#181;M) in the human wild type macrophages. No response to polySia avDP20 was detectable in the knockout macrophages. Data show mean +/- SEM. *** p &lt; 0.001, ANOVA followed by Bonferroni. Statistical analysis was done in relation to the LPS control. WT: no treatment n=6 and p&lt;0.0001, PolySia avDP20 1.5 &#181;M n=5 and p&lt;0.0001, LPS n=5, LPS/PolySia avDP20 0.15&#181;M n=5 and p=0.0002, LPS/PolySia avDP20 1.5&#181;M n=5 and p&lt;0.0001. Siglec11/16 KO: no treatment n=5 and p=0.022, PolySia avDP20 n=3 and p=0.063, LPS n=4, LPS/PolySia avDP20 0.15&#181;M n=3 and p=1.0, LPS/PolySia avDP20 1.5&#181;M n=4 and p=1.0.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-D</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-D</infon>
    <infon key="sourcedata_figure_dir">Figure_3-D</infon>
    <passage>
      <offset>0</offset>
      <text>D. Analysis of relative VEGFA protein release in human control and SIGLEC11/16 knockout THP1-macrophages. Released protein levels were reduced after 24 hours of co-treatment with LPS (1 &#181;g/ml) and polySia avDP20 (0.15 &#181;M and 1.5 &#181;M) in the human macrophages. Data show mean +/- SEM. * p &lt; 0.05, *** p &lt; 0.001, ANOVA followed by Bonferroni. Statistical analysis was done in relation to the LPS control. WT: no treatment n=9 and p&lt;0.0001, PolySia avDP20 1.5 &#181;M n=6 and p=0.009, LPS n=9, LPS/PolySia avDP20 0.15&#181;M n=6 and p=0.043, LPS/PolySia avDP20 1.5&#181;M n=7 and p=0.0001. Siglec11/16 KO: no treatment n=9 and p=0.349, PolySia avDP20 1.5 &#181;M n= 6 and p=0.249, LPS n=7, LPS/PolySia avDP20 0.15&#181;M n=6 and p=1.0, LPS/PolySia avDP20 1.5&#181;M n=7 and p=1.0.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-E</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-E</infon>
    <infon key="sourcedata_figure_dir">Figure_3-E</infon>
    <passage>
      <offset>0</offset>
      <text>E. Quantification of human control and SIGLEC11/16 knockout THP1-macrophages having ingested cellular debris. PolySia avDP20 (1.5 &#181;M) reduced the percentage of phagocytic cells having ingested drusen-like debris. No response to polySia avDP20 was detectable in the knockout macrophages. Data are presented as mean +/- SEM. n=6. *p &#8804; 0.05, *** p &#8804; 0.001, ANOVA followed by Bonferroni. Debris treated WT macrophages vs debris plus polySia avDP20 treated WT macrophages p = 0.028, debris plus polySia avDP20 treated WT macrophages vs KO macrophages p = 0.00012.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-F</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-F</infon>
    <infon key="sourcedata_figure_dir">Figure_3-F</infon>
    <passage>
      <offset>0</offset>
      <text>F. Prevention of superoxide release in activated human control and SIGLEC11/16 knockout THP1-macrophages by polySia avDP20. Cultured human THP1-macrophages were stimulated with RPE cell debris or co-stimulated with debris and polySia avDP20. Addition of debris stimulated the production of superoxide. 1.5 &#181;M polySia avDP20 completely prevented the release of superoxide induced by debris challenge. No response to polySia avDP20 was detectable in the knockout macrophages. Data are presented as mean +/- SEM. n=6. p* &#8804; 0.05, *** p &#8804; 0.001, ANOVA followed by Bonferroni. Untreated WT macrophages vs debris treated WT macrophages p = 0.037, debris treated WT macrophage vs debris plus polySia avDP20 1.5 &#181;M treated WT macrophages p &lt; 0.001, debris plus polySia avDP20 WT macrophages vs KO macrophages p = 0.001,</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-G</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-G</infon>
    <infon key="sourcedata_figure_dir">Figure_3-G</infon>
    <passage>
      <offset>0</offset>
      <text>G. PolySia avDP20 (0.15 to 50 &#181;M) was added to normal human serum (NHS) to evaluate any interference with activation of the classical complement pathway by IgM. Complement activation was determined by C3b deposition. PolySia avDP20 had no effect on C3b deposition induced by activation of the classical complement pathway. Data show mean +/- SEM. n = 3, n.s.= not significant.</text>
    </passage>
  </document>
  <document>
    <id>5286381 Figure_3-H</id>
    <infon key="sourcedata_document">2606</infon>
    <infon key="doi">10.15252/emmm.201606627</infon>
    <infon key="pmc_id">5286381</infon>
    <infon key="figure">Figure 3-H</infon>
    <infon key="sourcedata_figure_dir">Figure_3-H</infon>
    <passage>
      <offset>0</offset>
      <text>H. PolySia avDP20 inhibits the alternative complement pathway. PolySia avDP20 (0.15 to 50 &#181;M) was added to NHS and activation of the alternative pathway was induced by LPS. C3b deposition was monitored by ELISA. Data show mean +/- SEM (n = 4. * p &lt; 0.05, ** p &lt; 0.01, p***&lt;0.001, ANOVA followed by Bonferroni).</text>
    </passage>
  </document>
</collection>
